{"filing":{"accession_number":"0001628280-26-054273","cik":"0001770787","ticker":"TXG","company_name":"10x Genomics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"txg-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1770787/000162828026054273/txg-20260806.htm"},"events":[{"id":25884,"run_id":23500,"accession_number":"0001628280-26-054273","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"10x Genomics issued a press release on August 6, 2026 announcing financial results for Q2 2026 ended June 30, 2026, disclosing revenue of $151.0 million, gross margin of 74%, operating loss of $19.6 million, and net loss of $17.9 million, along with updated full-year 2026 revenue guidance of $610–$630 million. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1.","company_name":"10x Genomics, Inc.","ticker":"TXG","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26818,"accession_number":"0001628280-26-054273","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"10x Genomics issued a press release on August 6, 2026 announcing financial results for Q2 2026 ended June 30, 2026, disclosing revenue of $151.0 million, gross margin of 74%, operating loss of $19.6 million, and net loss of $17.9 million, along with updated full-year 2026 revenue guidance of $610–$630 million. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:40:54.343479+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26818,"accession_number":"0001628280-26-054273","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"10x Genomics issued a press release on August 6, 2026 announcing financial results for Q2 2026 ended June 30, 2026, disclosing revenue of $151.0 million, gross margin of 74%, operating loss of $19.6 million, and net loss of $17.9 million, along with updated full-year 2026 revenue guidance of $610–$630 million. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:40:54.343479+00:00","company_name":"10x Genomics, Inc.","ticker":"TXG","filing_date":"2026-08-06"}]}